VJHemOnc is committed to improving our service to you

ASH 2019 | GvHD prophylaxis: PTCY vs ATG in AML with allo-HSCT

VJHemOnc is committed to improving our service to you

Mohamad Mohty

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the retrospective analysis from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). The aim of this study was to compare graft-versus-host disease (GvHD) prophylaxis containing either post-transplant cyclophosphamide (PTCY) or anti-thymocyte globulin (ATG) in patients diagnosed with acute myeloid leukemia (AML) and undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-identical matched sibling donor (MSD). Prof. Mohty reveals PTCY is a valid option for GvHD prophylaxis, except for chronic GVHD for which a protective effect of ATG is confirmed. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter